Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more
Market Cap & Net Worth: Biomaxima (BMX)
Biomaxima (WAR:BMX) has a market capitalization of $12.00 Million (zł49.90 Million) as of March 18, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #29671 globally and #227 in its home market, demonstrating a 1.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomaxima's stock price zł11.90 by its total outstanding shares 4193118 (4.19 Million).
Biomaxima Market Cap History: 2015 to 2026
Biomaxima's market capitalization history from 2015 to 2026. Data shows growth from $3.87 Million to $12.00 Million (11.59% CAGR).
Biomaxima Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomaxima's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.20x
Biomaxima's market cap is 0.20 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
20.17x
Biomaxima's market cap is 20.17 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.87 Million | $21.97 Million | $1.45 Million | 0.18x | 2.66x |
| 2016 | $4.70 Million | $26.98 Million | $1.23 Million | 0.17x | 3.83x |
| 2017 | $4.90 Million | $31.57 Million | $805.68K | 0.16x | 6.08x |
| 2018 | $4.14 Million | $30.82 Million | -$481.98K | 0.13x | N/A |
| 2019 | $3.51 Million | $30.49 Million | -$13.51K | 0.12x | N/A |
| 2020 | $27.08 Million | $61.61 Million | $7.95 Million | 0.44x | 3.41x |
| 2021 | $26.04 Million | $79.09 Million | $10.24 Million | 0.33x | 2.54x |
| 2022 | $25.92 Million | $143.87 Million | $28.89 Million | 0.18x | 0.90x |
| 2023 | $16.56 Million | $46.79 Million | $586.00K | 0.35x | 28.26x |
| 2024 | $10.79 Million | $52.85 Million | $535.00K | 0.20x | 20.17x |
Competitor Companies of BMX by Market Capitalization
Companies near Biomaxima in the global market cap rankings as of March 18, 2026.
Key companies related to Biomaxima by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Biomaxima Historical Marketcap From 2015 to 2026
Between 2015 and today, Biomaxima's market cap moved from $3.87 Million to $ 12.00 Million, with a yearly change of 11.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł12.00 Million | -1.24% |
| 2025 | zł12.15 Million | +12.62% |
| 2024 | zł10.79 Million | -34.84% |
| 2023 | zł16.56 Million | -36.11% |
| 2022 | zł25.92 Million | -0.47% |
| 2021 | zł26.04 Million | -3.84% |
| 2020 | zł27.08 Million | +670.96% |
| 2019 | zł3.51 Million | -15.17% |
| 2018 | zł4.14 Million | -15.43% |
| 2017 | zł4.90 Million | +4.13% |
| 2016 | zł4.70 Million | +21.34% |
| 2015 | zł3.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biomaxima was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.00 Million USD |
| MoneyControl | $12.00 Million USD |
| MarketWatch | $12.00 Million USD |
| marketcap.company | $12.00 Million USD |
| Reuters | $12.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.